CoChat
Sign Up
Cited by 48

The DOI matches its Crossref record.

Gene Therapy for Human Malignant Brain Tumors

Rainov, Nikolai G., Ren, Huan·2003·The Cancer Journal
DOI 10.1097/00130404-200305000-00006
Open this paper in CoChat — free account

Abstract

Purpose Brain tumors were the first human malignancy to be targeted by therapeutic transfer of nucleic acids into somatic cells, a process also known as gene therapy. Malignant brain tumor cells in the adult brain have some unique biologic features, such as high mitotic activity on an essentially postmitotic background and virtually no tumor spread outside of the central nervous system. Brain tumors seem therefore to offer major advantages in the design of tumor-selective gene therapy strategies, and the role of gene therapy in malignant glioma has been investigated since the late 1980s, initially in numerous laboratory studies and later on in clinical trials. Design Retrovirus has been one of the earliest recombinant virus vectors used in brain tumors. Experiments in cell culture and in animal models have demonstrated the feasibility of retrovirus-mediated transduction and subsequent killing of glioma cells by toxic transgenes. Phase I and II clinical studies in patients with recurrent malignant glioma have shown a favorable safety profile and some efficacy of retrovirus-mediated gene therapy. However, the only prospective, randomized, phase III clinical study of retrovirus gene therapy in primary malignant glioma failed to demonstrate significant extension of progression-free or overall survival. Adenovirus- and herpes simplex virus type 1-based vectors have been actively investigated along with retrovirus, but their clinical use is still limited, mostly because of safety c…

Overview

Integrity signals

Registry

Crossref · 10.1097/00130404-200305000-00006

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 67

  1. Kramm, 1995, Brain Pathol, 5, 345, 10.1111/j.1750-3639.1995.tb00615.x · DOI
  2. Lam, 2001, Hum Mol Genet, 10, 777, 10.1093/hmg/10.7.777 · DOI
  3. Shapiro, 1998, Oncology, 12, 233
  4. Alavi, 2001, Expert Opin Biol Ther, 1, 239, 10.1517/14712598.1.2.239 · DOI
  5. Moolten, 1986, Cancer Res, 46, 5276
  6. Moolten, 1990, J Natl Cancer Inst, 82, 297, 10.1093/jnci/82.4.297 · DOI
  7. Ezzeddine, 1991, New Biol, 3, 608
  8. Short, 1990, J Neurosci Res, 27, 427, 10.1002/jnr.490270322 · DOI
  9. Rainov, 2001, Current Gene Ther, 1, 367, 10.2174/1566523013348445 · DOI
  10. Palu, 1999, Gene Ther, 6, 330, 10.1038/sj.gt.3300805 · DOI
  11. Wei, 1995, Hum Gene Ther, 6, 437, 10.1089/hum.1995.6.4-437 · DOI
  12. Zitvogel, 1994, Hum Gen Ther, 5, 1493, 10.1089/hum.1994.5.12-1493 · DOI
  13. Kim, 1994, Cancer Res, 54, 6053
  14. Alemany, 1999, Exp Cell Res, 252, 1, 10.1006/excr.1999.4623 · DOI
  15. Chiocca, 2002, Nat Rev Cancer, 2, 938, 10.1038/nrc948 · DOI
  16. Oldfield, 1993, Hum Gene Ther, 4, 39, 10.1089/hum.1993.4.1-39 · DOI
  17. Boviatsis, 1994, Hum Gene Ther, 5, 183, 10.1089/hum.1994.5.2-183 · DOI
  18. Tamiya, 1995, Gene Ther, 2, 531
  19. Ram, 1993, Cancer Res, 53, 83
  20. Ram, 1993, J Neurosurg, 79, 400, 10.3171/jns.1993.79.3.0400 · DOI
  21. Long, 1998, Hum Gene Ther, 9, 1165, 10.1089/hum.1998.9.8-1165 · DOI
  22. Shand, 1999, Hum Gene Ther, 10, 2325, 10.1089/10430349950016979 · DOI
  23. Boris-Lawrie, 1994, Ann NY Acad Sci, 716, 59, 10.1111/j.1749-6632.1994.tb21703.x · DOI
  24. 2000, Hum Gene Ther, 11, 2389, 10.1089/104303400750038499 · DOI
  25. Ram, 1997, Nat Med, 3, 1354, 10.1038/nm1297-1354 · DOI
  26. Klatzmann, 1998, Hum Gene Ther, 9, 2595
  27. Sandmair, 2000, Hum Gene Ther, 11, 2197, 10.1089/104303400750035726 · DOI
  28. Izquierdo, 1996, Gene Ther, 3, 491
  29. Packer, 2000, J Neurosurg, 92, 249, 10.3171/jns.2000.92.2.0249 · DOI
  30. Kramm, 2002, Neuropediatrics, 33, 6, 10.1055/s-2002-23592 · DOI
  31. Boothman, 1994, Int J Radiat Oncol Biol Phys, 30, 391, 10.1016/0360-3016(94)90019-1 · DOI
  32. Puumalainen, 1998, Hum Gene Ther, 9, 1769, 10.1089/hum.1998.9.12-1769 · DOI
  33. Harsh, 2000, Neurosurgery, 92, 804, 10.3171/jns.2000.92.5.0804 · DOI
  34. Kramer, 1997, Pediatr Neurosurg, 27, 230, 10.1159/000121259 · DOI
  35. Prados, 1998, Semin Surg Oncol, 14, 88, 10.1002/(SICI)1098-2388(199801/02)14:1<88::AID-SSU11>3.0.CO;2-5 · DOI
  36. Long, 1999, Hum Gene Ther, 10, 733, 10.1089/10430349950018490 · DOI
  37. Colombo, 1997, Stereotact Funct Neurosurg, 68, 245, 10.1159/000099933 · DOI
  38. Markert, 2000, Rev Med Virol, 10, 17, 10.1002/(SICI)1099-1654(200001/02)10:1<17::AID-RMV258>3.0.CO;2-G · DOI
  39. Markert, 2001, Herpes, 8, 17
  40. Rampling, 2000, Gene Ther, 7, 859, 10.1038/sj.gt.3301184 · DOI
  41. Harland, 2002, Gene Ther, 9, 1194, 10.1038/sj.gt.3301782 · DOI
  42. Markert, 2000, Gene Ther, 7, 867, 10.1038/sj.gt.3301205 · DOI
  43. Nanda, 2001, Prog Brain Res, 132, 699, 10.1016/S0079-6123(01)32111-8 · DOI
  44. Eck, 2001, Hum Gene Ther, 12, 97, 10.1089/104303401451013 · DOI
  45. Eck, 1996, Hum Gene Ther, 7, 1465, 10.1089/hum.1996.7.12-1465 · DOI
  46. Trask, 2000, Mol Ther, 1, 195, 10.1006/mthe.2000.0030 · DOI
  47. Bischoff, 1996, Science, 274, 373, 10.1126/science.274.5286.373 · DOI
  48. Dewey, 1999, Nat Med, 5, 1256, 10.1038/15207 · DOI
  49. Harrington, 2000, Clin Oncol, 12, 2
  50. Zerrouqi, 1996, Cancer Gene Ther, 3, 385
  51. Jacobs, 2001, Lancet, 358, 727, 10.1016/S0140-6736(01)05904-9 · DOI
  52. Voges, 2002, Hum Gene Ther, 13, 675, 10.1089/10430340252837260 · DOI
  53. Qureshi, 1999, Crit Rev Oncog, 10, 261
  54. Zlokovic, 1997, Neurosurg, 40, 805, 10.1097/00006123-199704000-00028 · DOI
  55. Blasberg, 1999, Q J Nucl Med, 43, 163
  56. Gambhir, 2000, Neoplasia, 2, 118, 10.1038/sj.neo.7900083 · DOI
  57. Sena-Esteves, 2002, J Gene Med, 4, 229, 10.1002/jgm.276 · DOI
  58. Rainov, 2001, Cancer Gene Ther, 8, 662, 10.1038/sj.cgt.7700355 · DOI
  59. Inamura, 1994, J Neurosurg, 81, 752, 10.3171/jns.1994.81.5.0752 · DOI
  60. Lemay, 1998, Hum Gene Ther, 9, 989, 10.1089/hum.1998.9.7-989 · DOI
  61. Barba, 1994, Proc Natl Acad Sci USA, 91, 4348, 10.1073/pnas.91.10.4348 · DOI
  62. Vile, 1997, Int J Cancer, 71, 267, 10.1002/(SICI)1097-0215(19970410)71:2<267::AID-IJC23>3.0.CO;2-D · DOI
  63. Mullen, 1998, Hum Gene Ther, 9, 2019, 10.1089/hum.1998.9.14-2019 · DOI
  64. Rainov, 2000, Gene Ther, 7, 1853, 10.1038/sj.gt.3301311 · DOI
  65. Parsa, 2001, Neurosurgery, 49, 681
  66. Dimeco, 2000, Neurosurg, 92, 419, 10.3171/jns.2000.92.3.0419 · DOI
  67. Valery, 2002, Neurology, 58, 1109, 10.1212/WNL.58.7.1109 · DOI

Cited by

Sorted by citations

Metadata

Authors
Rainov, N. G., & Ren, H.
Venue
The Cancer Journal
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2003-05
Volume
9
Issue
3
Pages
180-188
ISSN
1528-9117
DOI
10.1097/00130404-200305000-00006
Cited by
48
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review